The dengue testing market was valued at USD 528.13 million in 2021 and is expected to reach USD 7 22.45 million by 2027, registering a CAGR of 5.22% during the forecast period.
The COVID-19 pandemic has substantially impacted the dengue testing market. Dengue viruses and the virus that causes COVID-19 virus (SARS-CoV-2) cause similar symptoms in the early stages of infection. Thus, as a result, a major proportion of the population underwent dengue testing as the symptoms of COVID-19 and dengue were similar, boosting the market growth. Furthermore, several regions across the globe have reported a growing number of dengue cases amid the COVID-19 pandemic. For instance, as per a article titled, "Dengue amidst COVID‐19 in India: The mystery of plummeting cases", pubslihed in 2021, stated that dengue has shown an increasing trend in the number of cases in the country, therefore requiring urgent public policies to curb the disease. Thus, this has resulted in an increased demand for dengue testing procedures.
Further, the major factors fueling the market growth are the increasing incidences of dengue cases and growth in the number of awareness campaigns to educate about the ills of dengue. The overall incidence of dengue, as well as the explosive outbreaks of the disease, has been increasing dramatically over the last several years. For instance, as per the Pan American Health Organization, in the Region of the Americas in 2019, a total of 3,139,335 cases of dengue have been reported, equivalent to 321.58 cases per 100,000 population, including 1,538 deaths. As per the same source, out of the total cases, 1,367,353 were laboratory confirmed and 28,169 were classified as severe dengue.
Similarly, initiatives undertaken by the government and healthcare professionals to limit the spread of dengue is also expected to boost the market growth over the forecast period. For instance, the Department of Health (DOH), Philippines on June 15 led the conduct of the 2021 ASEAN Dengue Day Regional Forum in observance of the National Dengue Awareness Month with the theme “ASEAN Unite Against Dengue Amidst the COVID-19 Pandemic”. Participants in the forum highlighted their best practices for preventing and controlling dengue fever in the region amid the COVID-19 pandemic. Such initiatives by the government authorities are expected to boost the demand for dengue testing diagnostics, thereby contributing to market growth.
Nevertheless, the unavailability of effective diagnostic tools and the high price of existing test kits are the factors restraining the market growth.
Key Market Trends
ELISA-based Tests Segment is Anticipated to Hold a Significant Share of the Market
By product type, the ELISA-based tests segment is anticipated to hold a significant share of the market. Enzyme-linked immunosorbent assay (ELISA) is one of the most common and widely accepted methods for diagnosing dengue. The test measures the presence of anti-DENV IgM or IgG antibodies in patient serum. The early and timely diagnosis and management of dengue has the potential to reduce the risk of morbidity and mortality rates from severe forms of dengue disease as well as decrease the risk of wider outbreaks.
ELISA being the standard method can detect NS1 antigens and has the capability to differentiate between the four dengue virus serotypes. Thus, the use of ELISA for dengue testing is expected to increase. For instance, in February 2022, the Health Department in India has issued directions to private labs and hospitals to get only ELISA confirmatory tests done at government labs due to which private labs have been asked to send samples for the ELISA test if patients test positive for dengue through other initial tests.
Further, technological advancements in the ELISA platforms such as robust test kits, offered by several major players in the market is driving the growth of the market. For instance, PANBIO DENGUE IGG INDIRECT ELISA, a test kit offered by Abbott is used to detect IgG antibodies to dengue antigen serotypes (1, 2, 3, and 4) in serum as an aid to the clinical laboratory diagnosis of patients with clinical symptoms and past exposure consistent with dengue fever.
Thus, considering all the above-mentioned factors, the segment is expected to witness steady growth over the forecast period.
Asia Pacific is Fastest Growing Market in the Dengue Testing Market
Asia-Pacific is expected to be the fastest-growing market in the dengue testing market owing to the increasing prevalence of the disease infections within the region. For instance, as per the data published by European Centre for Disease Prevention and Control (ECDC) 2022, approximately 313 cases in Indonesia, 816 cases in Sri Lanka, 1,286 cases in Timor-Leste, and 2,440 cases were reported in Vietnam.
Similarly, as per a news article published in February 2022, in India, there were 164,103 new dengue cases in 2021. Likewise, according to the article published in 2019 by Qinlong Jing et al, it was found that, in recent years, southern China has been experiencing a high frequency of transmission and recurring epidemics of dengue, especially in Guangzhou, which accounts for 69.2% of reported cases in mainland China. As a result, such increasing incidences of dengue are expected to boost the demand for diagnostic tests within the region, thereby, driving the market growth in the near future. Moreover, such outbreaks across various regions in Asia-Pacific have led several companies to develop dengue diagnostic test kits. For instance, in November 2021, Achiko initiated the development of a dengue fever diagnostic test by applying its DNA aptamer technology platform.
Thus, considering all the above-mentioned factors, along with the increasing number of patients in the region, the testing of dengue is also expected to rise and boost the growth of the market.
There has been a presence of a considerable number of companies that are significantly contributing to market growth. The major companies that are functioning in the global dengue testing market include Abbott Laboratories, NovaTec Immundiagnostica GmbH, Euroimmun AG (PerkinElmer), F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., and InBios International, Inc.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increase Incidences of Dengue Cases
4.2.2 Increasing Awareness Campaigns to Educate About the Ills of Dengue
4.3 Market Restraints
4.3.1 Unavailability of Effective Diagnostic Tools
4.3.2 High Price of Existing Test Kits
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.1 ELISA-based Tests
5.1.2 RT-PCR based Tests
5.1.3 Dengue IgG/IgM Rapid Test
5.1.4 Other Tests
5.2 By End User
5.2.2 Diagnostic Centers
5.3.1 Asia Pacific
18.104.22.168 Sri Lanka
22.214.171.124 Rest of Asia-Pacific
126.96.36.199 Rest of Americas
6.1.1 Abbott Laboratories
6.1.2 Abnova Corporation
6.1.3 PerkinElmer, Inc (Euroimmun AG)
6.1.4 Certest Biotec S.L.
6.1.6 F. Hoffmann-La Roche Ltd.
6.1.7 InBios International, Inc.
6.1.8 NovaTec Immundiagnostica GmbH
6.1.9 OriGene Technologies
6.1.10 Thermo Fisher Scientific Inc.
6.1.11 Immundiagnostik AG
6.1.12 Quest Diagnostics
6.1.13 OriGene Technologies
A selection of companies mentioned in this report includes:
- Abbott Laboratories
- Abnova Corporation
- PerkinElmer, Inc (Euroimmun AG)
- Certest Biotec S.L.
- F. Hoffmann-La Roche Ltd.
- InBios International, Inc.
- NovaTec Immundiagnostica GmbH
- OriGene Technologies
- Thermo Fisher Scientific Inc.
- Immundiagnostik AG
- Quest Diagnostics
- OriGene Technologies